Hims

Provider Profile Name: Hims (Weight Loss by Hims)
Parent Company: Hims & Hers Health, Inc. (NYSE: HIMS)
Website: hims.com
Founded: 2017
Provider Type: Telehealth — Virtual Only, Men’s Health Platform with Weight Management
Headquarters: San Francisco, CA

Operating Details

• Fully virtual — online assessment, licensed provider review, home delivery
• No insurance required; FSA/HSA eligible
• No monthly membership fee — all plans prepaid upfront
• Not available in Alabama, Arkansas, Louisiana, or Mississippi; GLP-1s not yet available in all remaining states
• Two-day shipping included at no extra cost in temperature-controlled packaging
• Compounded medications not FDA-approved; major regulatory and legal events in 2025–2026 (see below)

Approach Hims is arguably the most recognizable name in men’s telehealth, famous for normalizing the conversation around hair loss and ED, and has brought that same digital-first approach to weight management. The platform offers both injectable GLP-1s and oral medication kits for men, along with app-based lifestyle support. The weight loss program has been one of the most publicly eventful in the GLP-1 telehealth space over the past year, with a sequence of regulatory and legal actions that significantly reshaped the platform’s product offering.

About the Company

Hims launched its weight loss program in 2024 as part of a broader expansion into chronic condition management. Starting when drugs like semaglutide and tirzepatide went into shortage, Hims began selling compounded GLP-1 injections in May 2024, taking advantage of a regulatory provision allowing compounding of drugs on the FDA’s official shortage list.

Timeline of Key Regulatory and Legal Events:

September 9, 2025 — FDA Warning Letter: The FDA issued a warning letter to Hims & Hers Health on September 9, 2025, finding false or misleading claims on its website about compounded semaglutide and tirzepatide — including phrases such as “Same active ingredient as Ozempic and Wegovy” and “Clinically proven ingredients,” which imply the compounded products are the same as FDA-approved drugs when they are not.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

February 2026 — Compounded Semaglutide Pill Launch, DOJ Referral, and Withdrawal: In early February 2026, Hims announced the launch of a compounded semaglutide pill at $49 for the first month — roughly $100 less than Novo Nordisk’s newly approved Wegovy oral pill. The announcement triggered swift federal action. The HHS General Counsel announced on X that his agency had referred Hims & Hers to the Department of Justice for potential violations of the Federal Food, Drug, and Cosmetic Act and applicable criminal provisions. Hims pulled the product within days, stating it had “decided to stop offering access to this treatment” following constructive conversations with stakeholders. 

February 9, 2026 — Novo Nordisk Lawsuit: Novo Nordisk filed suit against Hims & Hers for infringing US Patent No. 8,129,343 through the marketing and sale of compounded semaglutide products, alleging illegal mass compounding and deceptive marketing practices. Novo cited internal testing finding impurity levels as high as 86% in injectable compounded semaglutide products and up to 75% in compounded oral versions.

March 9, 2026 — Deal with Novo Nordisk: In a significant pivot, Novo Nordisk and Hims & Hers announced an agreement on March 9, 2026 to offer various doses of Ozempic through the Hims platform for direct-to-consumer customers — effectively moving Hims away from compounded semaglutide toward branded, FDA-approved medication access.

GLP-1 Offerings and Weight Loss Services

As of the writing of this article, Hims’ GLP-1 product lineup is in active transition. The platform’s stated current offerings include:

Injectable GLP-1s:

• Compounded semaglutide (injectable), Wegovy, Ozempic, Zepbound, Mounjaro, and generic liraglutide — available for eligible patients depending on state and current supply
• Following the March 2026 Novo Nordisk deal, access to branded Ozempic is now part of the platform

Oral Medication Kits:

• Personalized oral kits combining medications such as bupropion/naltrexone, metformin, and topiramate — targeting food noise, slow metabolism, and appetite regulation without injections

App and Support:

• 360° care including nutritional principles, behavioral programs, and custom lessons in the Hims app; answers to questions, check-ins, and medication adjustments — all included at no additional cost
• Prescription anti-nausea medication (ondansetron) included for eligible patients at no extra cost

Patients should verify current medication availability directly on hims.com, as the product catalog has changed materially in early 2026 and may continue to evolve.

Pricing — and What Reviewers Say

Pricing for weight loss plans starts at $69/month for oral medication kits with a 10-month plan paid in full upfront; GLP-1 injectable plans start at $199/month with a 6-month plan paid in full upfront.

• Oral medication kits: from $69/month (10-month prepaid)
• Compounded semaglutide injectable: from $199/month (6-month prepaid); month-to-month plans available but significantly more expensive
• No monthly membership fee; lab work $75–$100 if required, not included

What reviewers say about pricing: The $199/month entry point for compounded injectable semaglutide is consistently cited as competitive, and the “set it and forget it” upfront payment model appeals to patients who want a locked-in rate without month-to-month billing uncertainty. However, the sticker shock of the full upfront payment — often $1,200 or more for a 6-month plan — is a common complaint for new users expecting a monthly bill.

Reviews from Trustpilot and Google

No specific Trustpilot review count was recovered through research for this article — patients should search hims.com on Trustpilot for current ratings. The platform’s public reputation in the weight loss space has been dominated in early 2026 by the regulatory and legal events described above rather than by consumer review volume.

The oral medication kit program draws generally positive feedback for patients who want injection-free options, and the app experience is widely considered among the best-in-class for telehealth weight management platforms. Concerns center on the prepaid structure and the uncertainty created by the platform’s rapidly shifting compounded vs. branded medication lineup.

Compounding Pharmacies Used

Hims has historically partnered with large-scale compounding facilities for its semaglutide and tirzepatide products. The company’s compounded product offering is under active legal and regulatory scrutiny, with Novo Nordisk alleging that Hims continues to use inauthentic active pharmaceutical ingredients in its injectable semaglutide products. Patients who have been receiving compounded semaglutide through Hims should ask directly about the current pharmacy fulfilling their prescription and its regulatory status, particularly given the platform’s transition toward branded medications following the March 2026 Novo Nordisk deal.

Note: Hims has the most complex regulatory history of any platform in this review series. It received an FDA warning letter in September 2025 for misleading compounded semaglutide marketing claims, launched a compounded semaglutide pill in February 2026 that was referred to the DOJ within days and pulled within 48 hours, was sued by Novo Nordisk for patent infringement, and then reached a deal with Novo Nordisk in March 2026 to offer branded Ozempic directly through the platform. The product catalog is in active transition — confirm current offerings, pharmacy sourcing, and pricing directly at hims.com before enrolling. Compounded medications are not FDA-approved. Always consult a licensed medical provider before beginning any GLP-1 program.